Product Description
A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called taxanes.
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer|Breast Cancer|Lymphoma, Non-Hodgkin
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT00044525 | P2 |
Completed |
Breast Cancer |
2004-02-01 |
|
NCT00044538 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
None |
|
NCT00044551 | P2 |
Completed |
Lymphoma, Non-Hodgkin |
None |